Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Depreciation and Depletion (2019 - 2025)

Black Diamond Therapeutics' Depreciation and Depletion history spans 5 years, with the latest figure at $66000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 22.35% year-over-year to $66000.0; the TTM value through Dec 2025 reached $325000.0, down 5.25%, while the annual FY2025 figure was $325000.0, 5.25% down from the prior year.
  • Depreciation and Depletion reached $66000.0 in Q4 2025 per BDTX's latest filing, down from $86000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $87000.0 in Q1 2025 to a low of $19000.0 in Q1 2021.
  • Average Depreciation and Depletion over 3 years is $76333.3, with a median of $86000.0 recorded in 2024.
  • Peak YoY movement for Depreciation and Depletion: surged 90.0% in 2021, then fell 22.35% in 2025.
  • A 3-year view of Depreciation and Depletion shows it stood at $19000.0 in 2021, then surged by 347.37% to $85000.0 in 2024, then fell by 22.35% to $66000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Depreciation and Depletion are $66000.0 (Q4 2025), $86000.0 (Q3 2025), and $86000.0 (Q2 2025).